Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat oncology indications, announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug application for ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors.
June 4, 2020
· 4 min read